Skip to main content
. 2021 Jan 20;9(1):e001698. doi: 10.1136/jitc-2020-001698

Figure 2.

Figure 2

Exosomal PD-L1 induces acquired resistance to anti-PD-1/PD-L1 therapy. Exosomes carrying PD-L1 limit effectiveness of anti-PD-1/PD-L1 therapy through binding to antibodies and suppression of T-cell activity. However, elimination of PD-L1 exosomes can improve anti-PD-1/PD-L1 therapy. IFN-γ, interferon-gamma; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.